ClinicalTrials.gg
Active, not recruitingNCT03341936Updated Jun 18, 2025Results posted

Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN

A Phase 2 interventional study of Nivolumab and Lirilumab in Squamous Cell Carcinoma of the Head and Neck, sponsored by Dana-Farber Cancer Institute. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-18.

Sponsored by Dana-Farber Cancer Institute · Phase 2, Interventional, and Treatment

How we know · 5 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
29
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 24 studies in Squamous Cell Carcinoma of Head and Neck by Dana-Farber Cancer Institute — 3 open to participants now, 5 under way, none of them phase 3. Squamous Cell Carcinoma of Head and Neck · Dana-Farber Cancer Institute.

Enrollment
9th of 23
29 · median 29
Started
2018
the only one that year
Phase 2
10 of 24
3 open now
Registered
18th of 24
by date

Among the 24 studies in Squamous Cell Carcinoma of Head and Neck by Dana-Farber Cancer Institute, this one is the 9th largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2018, is one of 10 in phase 2, and was the 18th registered.

Squamous Cell Carcinoma of Head and Neck

2,020 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

3 of the 24 studies in Squamous Cell Carcinoma of Head and Neck by Dana-Farber Cancer Institute are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Squamous Cell Carcinoma of Head and Neck by Dana-Farber Cancer Institute, or all of them as a file.
02

Study summary

This research study is studying a combination of two immunotherapy drugs, as a possible treatment for locoregionally recurrent squamous cell carcinoma of the head and neck.

The immunotherapy drugs involved in this study are:

  • Nivolumab (Opdivo™)
  • Lirilumab
Read the detailed description

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug or combination of drugs to learn whether it works in treating a specific disease. "Investigational" means that the drug/s is being studied.

The purpose of this study is to evaluate effectiveness (how well the drug/s work) of nivolumab in combination with lirilumab in participants with SCCHN.

Nivolumab and lirilumab are types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells. Both nivolumab and lirilumab have been demonstrated to activate the immune system to attack cancer cells in participants with different types of cancers.

In November, 2016, the Food and Drug Administration (FDA) approved nivolumab for the treatment of participants with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Lirilumab is not FDA approved as of now.

03

Conditions studied

  • Squamous Cell Carcinoma of the Head and Neck

Keywords

  • Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must have or cytologically confirmed locoregionally recurrent squamous cell carcinoma of the head and neck (including any primary site, such as oral cavity, oropharynx, larynx or hypopharynx, and nasopharyngeal carcinoma)
  • Must be a candidate for salvage surgery
  • Willing to provide blood and tissue from diagnostic and at the time of surgery
  • Has documented disease-free interval (DFI) > 8 weeks after completion of initial therapy; DFI is from the time of completion of initial treatment to the diagnosis of local or locoregional recurrence
  • Any HPV status or smoking history is permitted. Oropharyngeal cancer patients are required to undergo HPV testing with p16 immunohistochemistry and/or confirmatory HPV PCR or ISH testing
  • Age 18 years or older
  • performance status ≤2 ( ≥60%, see Appendix A)
  • Participant must have normal organ and marrow function as defined below within 21 days prior to study registration:

    • leukocytes ≥3,000/mcL
    • ≥1,500/mcL
    • ≥100,000/mcL
    • total ≤2.0 g/dL
    • (SGOT)/ALT(SGPT) ≤2.5 × institutional
    • creatinine within normal institutional limits OR
    • ≥60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal
  • Ability to understand and the willingness to sign a written document
  • Women of (WOCBP) must agree to use appropriate method(s) of . WOCBP should plan to use an adequate method to avoid pregnancy for 5 months (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of drug
  • Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 iu/l or equivalent units of hcg) within 24 hours prior to the start of nivolumab
  • "Women of childbearing potential (WOCBP)" is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not . Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL
  • Men who are sexually active with WOCBP must agree to use any contraceptive method with a failure rate of less than 1% per year. Men who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of investigational product. Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraception

Exclusion criteria

Exclusion Criteria:

  • Existing significant conditions. Patients with a history of Hashimoto thyroiditis who are stable on replacement hormone therapy are not excluded. Patients cannot be on long-term (> 4 weeks) at doses exceeding prednisone 20 mg (or its equivalent) prior to enrollment. Short-term corticosteroid dosing is permitted as long as steroids are discontinued within 2 weeks of study enrollment.
  • Subject who has had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
  • Subject who has been treated with immunotherapy. This includes prior treatment with , anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
  • Subject with known should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. However, baseline brain imaging is not required prior to enrollment in the study if patients are asymptomatic.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Known carrier or a diagnosis of immunodeficiency. Any positive test result for virus or virus indicating presence of virus, eg, Hepatitis B surface antigen (HBsAg, Australia antigen) positive, or Hepatitis C antibody (anti-HCV) positive (except if HCV-RNA negative).
  • Known non-infectious pneumonitis or any history of interstitial lung disease.
  • Receipt of a within 30 days of start of study treatment
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Nivolumab+Lirilumab

    * The drugs will be administered intravenously. A single dose of Nivolumab and Lirilumab will be administered prior Salvage surgical resection. * In Cycle 1-3: Nivolumab will be administered on Days 1 and 15 and lirilumab will be administered on Day 1 of each 28 day long cycle * In Cycle 4-6 and beyond: Nivolumab and lirilumab will be administered on Day 1 of each 28 day long cycle.

    Drug: Nivolumab · Drug: Lirilumab

Interventions

  • Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells

  • Lirilumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells

06

What researchers measure

Primary outcomes

  1. 1-Year Disease-Free Survival Percentage

    The percentage of patients who were alive and disease free at one year past salvage surgery. Patients who were alive at last contact prior to the one year mark are censored. Data analysis conducted through Kaplan Meier methods.

    Time frame: 1 year since salvage surgery, up to 1 year and 23 days since treatment start

Secondary outcomes

  1. Response at Time of Salvage Surgery

    Response is classified using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) Complete Response - Disappearance of all lesions and pathologic lymph nodes. Partial Response - At least 30% decrease in sum of longest diameters (SLD) for the target lesions, no new lesions, and no progression of non-target lesions. Progressive Disease - At least 20% increase in SLD compared to smallest SLD in study or progression of non-target lesions or development of new lesions Stable Disease - No Partial Response and no Progressive Disease.

    Time frame: At the time of salvage surgery, up to 23 days from treatment start date.

  2. Median Disease-Free Survival Rate

    The median time that patients were alive and disease free after salvage surgery. Patients who were alive at last contact are censored at last contact. Data analysis conducted through Kaplan Meier methods

    Time frame: Up to 27.2 months post salvage surgery, up to 28 months total.

  3. 1-Year Overall Survival Percentage

    Percentage of participants who were alive at 1 year since salvage surgery. Patients alive at last contact prior to 1 year were censored.

    Time frame: 1 year post salvage surgery, up to 1 year and 23 days post treatment start.

  4. Median Change in Programmed Cell Death Ligand - 1 Combined Positive Score

    The median change in Programmed Cell Death Ligand - 1 Combined Positive Score (PD-L1 CPS) from baseline to surgery. The score is derived from tumor tissue samples that measures the presence of both tumor and immune cell staining for the PD-L1 marker. Scored from 0-100, a higher score suggests the patient might respond better to treatment. A pathological responder is defined as having less than 50% viable tumor at the time of surgery.

    Time frame: Measured at baseline and then at time of salvage surgery, up to 23 days.

07

Results

Posted Jun 16, 2022

Participant flow

Enrollment Period March 2018 to May 2020

Participant flow — Overall Study
MilestoneNivolumab+Lirilumab
Started29
Treated28
Completed18
Not completed11
Withdrew: Ineligible1
Withdrew: Disease progression2
Withdrew: Withdrew consent4
Withdrew: Non-compliance1
Withdrew: Physician decision1
Withdrew: Withdrawal by subject1
Withdrew: Other1

Outcome measures

Primary1-Year Disease-Free Survival Percentage

The percentage of patients who were alive and disease free at one year past salvage surgery. Patients who were alive at last contact prior to the one year mark are censored. Data analysis conducted through Kaplan Meier methods.

Time frame:
1 year since salvage surgery, up to 1 year and 23 days since treatment start
Reported as:
Number · percentage of participants
1-Year Disease-Free Survival Percentage
percentage of participantsNivolumab+Lirilumab
1-Year Disease-Free Survival Percentage55.2 (34.8 to 71.7)
SecondaryResponse at Time of Salvage Surgery

Response is classified using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) Complete Response - Disappearance of all lesions and pathologic lymph nodes. Partial Response - At least 30% decrease in sum of longest diameters (SLD) for the target lesions, no new lesions, and no progression of non-target lesions. Progressive Disease - At least 20% increase in SLD compared to smallest SLD in study or progression of non-target lesions or development of new lesions Stable Disease - No Partial Response and no Progressive Disease.

Time frame:
At the time of salvage surgery, up to 23 days from treatment start date.
Reported as:
Count of participants · Participants
Response at Time of Salvage Surgery
ParticipantsNivolumab+Lirilumab
Stable Disease27
Progressive Disease1
SecondaryMedian Disease-Free Survival Rate

The median time that patients were alive and disease free after salvage surgery. Patients who were alive at last contact are censored at last contact. Data analysis conducted through Kaplan Meier methods

Time frame:
Up to 27.2 months post salvage surgery, up to 28 months total.
Reported as:
Median · months
Median Disease-Free Survival Rate
monthsNivolumab+Lirilumab
Median Disease-Free Survival Rate12.9 (8.18 to NA)
Secondary1-Year Overall Survival Percentage

Percentage of participants who were alive at 1 year since salvage surgery. Patients alive at last contact prior to 1 year were censored.

Time frame:
1 year post salvage surgery, up to 1 year and 23 days post treatment start.
Reported as:
Number · percentage of participants
1-Year Overall Survival Percentage
percentage of participantsNivolumab+Lirilumab
1-Year Overall Survival Percentage85.7 (66.3 to 94.4)
SecondaryMedian Change in Programmed Cell Death Ligand - 1 Combined Positive Score

The median change in Programmed Cell Death Ligand - 1 Combined Positive Score (PD-L1 CPS) from baseline to surgery. The score is derived from tumor tissue samples that measures the presence of both tumor and immune cell staining for the PD-L1 marker. Scored from 0-100, a higher score suggests the patient might respond better to treatment. A pathological responder is defined as having less than 50% viable tumor at the time of surgery.

Time frame:
Measured at baseline and then at time of salvage surgery, up to 23 days.
Reported as:
Median · score
Median Change in Programmed Cell Death Ligand - 1 Combined Positive Score
scoreNivolumab+Lirilumab
Responder2.5 (-45 to 75)
Non-Responder0 (-45 to 49)

Adverse events

Collected over All-Cause Mortality was monitored for 1 year post salvage surgery, up to 1 year and 23 days post treatment start. Serious Adverse Events and Other (Not Including Serious) Adverse Events were monitored from baseline to end of adjuvant therapy, up to 9 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nivolumab+Lirilumab7/28 (25%)12/28 (42.9%)28/28 (100%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventNivolumab+Lirilumab
DyspneaRespiratory, thoracic and mediastinal disorders4/28
DysphagiaGastrointestinal disorders3/28
Wound infectionInfections and infestations2/28
Productive coughRespiratory, thoracic and mediastinal disorders2/28
Cardiac arrestCardiac disorders1/28
Chest pain - cardiacCardiac disorders1/28
Myocardial infarctionCardiac disorders1/28
NauseaGastrointestinal disorders1/28
Infusion related reactionGeneral disorders1/28
Lung infectionInfections and infestations1/28
Most frequent other events
Showing 10 of 133
Most frequent other events
EventNivolumab+Lirilumab
DysphagiaGastrointestinal disorders27/28
FatigueGeneral disorders20/28
HypothyroidismEndocrine disorders18/28
Respiratory, thoracic and mediastinal disorders - Other, specifyRespiratory, thoracic and mediastinal disorders15/28
PainGeneral disorders14/28
Voice alterationRespiratory, thoracic and mediastinal disorders13/28
DiarrheaGastrointestinal disorders11/28
Dry mouthGastrointestinal disorders11/28
Neck painMusculoskeletal and connective tissue disorders10/28
CoughRespiratory, thoracic and mediastinal disorders10/28

Baseline characteristics

Age, Continuous
Age, Continuous(years)Nivolumab+Lirilumab
Median66 (36 to 85)
Sex: Female, Male
Sex: Female, Male(Participants)Nivolumab+Lirilumab
Female5
Male23
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nivolumab+Lirilumab
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White26
More than one race0
Unknown or Not Reported1
08

Study locations

1 site
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Jul 2021, 39 months.

Results were first posted in Jun 2022, 11 months after primary completion.

Of 298 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's 39 months is below that.

Counting every sponsor, half of 365 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2017
First posted
Nov 14, 2017
StartActual
Mar 15, 2018
Primary completionActual
Jul 6, 2021
CompletionEst.
Jul 6, 2026
Results first posted
Jun 16, 2022
Last update
Jun 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03341936
Responsible party
Glenn J. Hanna (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Nov 14, 2017
Start date
Mar 15, 2018
Primary completion
Jul 6, 2021
Completion
Jul 6, 2026 (estimated)
Results posted
Jun 16, 2022
Last update
Jun 18, 2025

Study contacts

Glenn J. Hanna, MD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lirilumab

Start the discussion